Out of Spec Investigations Cited in 30% of FY 1997 Warning Letters
Executive Summary
The pharmaceutical industry continues to struggle with the interpretation of FDA's requirements for out-of-specification result investigations, as indicated by good manufacturing practices warning letters issued to firms in FY 1997.